Medically Necessary Lead Poisoning Treatment
Edetate Calcium Disodium (Calcium EDTA; Calcium Disodium Versenate) is considered medically necessary when ALL of the following criteria are met:
ALL of the following
The indication is acute or chronic lead poisoning, including lead encephalopathy.
Approve for 1 month.
Both dosing requirements
The dose is up to 1000 mg/m²/day for 5 days, followed by a second 5-day course given 2 to 4 days later if indicated.
If additional courses are needed, courses are given no more frequently than every 4 weeks.
Services for or in connection with an injury or illness arising out of, or in the course of, any employment for wage or profit are explicitly excluded under most Cigna benefit plans. Therefore, treatment of metal toxicity that occurs as a result of occupational exposure is generally not covered.
Treatment of mercury toxicity attributed to dental amalgam fillings is not covered. FDA issued updated dental amalgam recommendations in 2020, recommending that certain high-risk groups avoid new dental amalgam when possible and appropriate. However, FDA also stated that it does not recommend removal or replacement of existing amalgam fillings in good condition unless medically necessary, because removal may temporarily increase mercury vapor exposure and may result in loss of healthy tooth structure. FDA's 2020 dental amalgam communication does not establish edetate calcium disodium as treatment for alleged mercury toxicity from dental amalgam fillings.
Treatment of poisoning caused by other heavy metals, including aluminum, arsenic, cadmium, cobalt, manganese, mercury, plutonium, or uranium toxicity, is not covered when the condition is not otherwise addressed in the Medically Necessary criteria. Treatment is not clinically supported.
Edetate Calcium Disodium for atherosclerotic vascular disease is not medically necessary. Chelation therapy with ethylene diamine tetra-acetic acid (EDTA) has been proposed for atherosclerotic cardiovascular disease; however, evidence remains insufficient to support routine use. A 2022 systematic review, Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review, searched MEDLINE, Embase, and Cochrane through October 2021 and identified 24 studies, including four randomized clinical trials. The authors reported mixed findings, with differences across infusion regimens and study designs limiting interpretation, and concluded that additional research was needed. TACT2, a randomized clinical trial in patients with diabetes and prior myocardial infarction, found that EDTA-based chelation reduced median blood lead levels but did not reduce major adverse cardiovascular events compared with placebo. The primary composite outcome occurred in 35.6% of the chelation group and 35.7% of the placebo group, with adjusted HR 0.93, 95% CI 0.76 to 1.16, and p=0.53.
Edetate Calcium Disodium for autism spectrum disorders is not medically necessary. Chelation has been proposed based on the theory that removal of heavy metals may improve symptoms; however, a Cochrane review found no clinical trial evidence that pharmaceutical chelation is an effective intervention for autism spectrum disorder symptoms. The review also noted prior serious adverse events, including hypocalcemia, renal impairment, and reported death, and concluded that risks currently outweigh proven benefits. The proposal is based on the theory that the chelating agent will remove mercury thought to be contained in tissue after early childhood vaccinations in children with autism spectrum disorder. Several studies have examined the relationship of mercury to autism spectrum disorder, but no consistent associations have been identified. There is insufficient evidence in the peer-reviewed literature regarding the efficacy of chelation therapy for treatment of autism spectrum disorder.
Edetate Calcium Disodium for treatment of mercury toxicity attributed to dental amalgam fillings is not medically necessary. FDA's 2020 dental amalgam communication does not establish edetate calcium disodium as treatment for alleged mercury toxicity from dental amalgam fillings.
Edetate Calcium Disodium for heavy-metal poisoning or toxicity not otherwise addressed in the Medically Necessary criteria is not medically necessary. Treatment of poisoning caused by other heavy metals, including aluminum, arsenic, cadmium, cobalt, manganese, mercury, plutonium, or uranium toxicity, is not clinically supported. This list may not be all inclusive; criteria will be updated as new published data are available.